RxDoctor Payments Data

Trenton Williams

Nurse Practitioner · Orem, UTNPI 1184280869

Payments from drug & device makers

$1,036in general payments, 2019–2025

Across 42 payments — averaging $24.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$255
  • Boston Scientific$139
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$118
  • Medela LLC$114
  • Johnson & Johnson$102
  • Pfizer$59
  • plus $250 from 9 others

What the payments were for

  • Food & beverage$1,036100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,036 in reported general payments places this provider in the 75th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$4,572
Medicare patients
40
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan48$47,417
EliquisApixaban34$31,060
XareltoRivaroxaban26$20,870
FarxigaDapagliflozin Propanediol17$9,684
BrilintaTicagrelor19$8,953
Flecainide Acetate20$1,635
Atorvastatin Calcium116$1,233
Metoprolol Succinate93$875
Losartan Potassium59$636
ClopidogrelClopidogrel Bisulfate41$545
Potassium Chloride23$499
Torsemide13$472
Nifedipine ErNifedipine14$331
Lisinopril31$283
Carvedilol37$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$255$47,41748 claims
PfizerEliquis$59$31,06034 claims
Johnson & JohnsonXarelto$102$20,87026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Orem

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →